6.2.1.1	3T3-L1 cell	marked induction of AceCS1 mRNA and protein during differentiation of 3T3-L1 cells, neither AceCS2 mRNA nor protein is detected in undifferentiated or differentiated 3T3-L1 cells	652101	
6.2.1.1	A-549 cell	-	744656	
6.2.1.1	ACHN cell	-	744665	
6.2.1.1	adipose tissue	-	563, 572	
6.2.1.1	AsPC-1 cell	-	744656	
6.2.1.1	B-16 cell	cells express higher levels of cytosolic acetyl-CoA synthetase ACSS2 under hypoxia than normoxia. Knockdown of ACSS2 by RNA interference in tumor cells enhances tumor cell death under long-term hypoxia in vitro. The ACSS2 suppression slows tumor growth in vivo. Tumor cells excrete acetate and the quantity increases under hypoxia, the pattern of acetate excretion follows the expression pattern of ACSS2. The ACSS2 knockdown leads to a corresponding reduction in the acetate excretion in tumor cells	703038	
6.2.1.1	bacteroid	from Glycine max L. cv. Williams inoculated with Bradyrhizobium japonicum	568	
6.2.1.1	brain	-	562, 563, 572	
6.2.1.1	brain	AceCS2, low activity	652101	
6.2.1.1	breast tumor cell	-	744620	
6.2.1.1	BT-474 cell	-	744620, 744656	
6.2.1.1	C127I cell	cells express higher levels of cytosolic acetyl-CoA synthetase ACSS2 under hypoxia than normoxia. Knockdown of ACSS2 by RNA interference in tumor cells enhances tumor cell death under long-term hypoxia in vitro. The ACSS2 suppression slows tumor growth in vivo. Tumor cells excrete acetate and the quantity increases under hypoxia, the pattern of acetate excretion follows the expression pattern of ACSS2. The ACSS2 knockdown leads to a corresponding reduction in the acetate excretion in tumor cells	703038	
6.2.1.1	CAD cell	-	745887	
6.2.1.1	Colon-26 cell	cells express higher levels of cytosolic acetyl-CoA synthetase ACSS2 under hypoxia than normoxia. Knockdown of ACSS2 by RNA interference in tumor cells enhances tumor cell death under long-term hypoxia in vitro. The ACSS2 suppression slows tumor growth in vivo. Tumor cells excrete acetate and the quantity increases under hypoxia, the pattern of acetate excretion follows the expression pattern of ACSS2. The ACSS2 knockdown leads to a corresponding reduction in the acetate excretion in tumor cells	703038	
6.2.1.1	commercial preparation	highly purified enzyme	693035	
6.2.1.1	commercial preparation	Sigma and Boehringer Mannheim	550	
6.2.1.1	culture condition:maltose-grown cell	-	744177	
6.2.1.1	DU-145 cell	-	744620	
6.2.1.1	epididymis	-	649297	
6.2.1.1	fibroblast	-	746321	
6.2.1.1	fibroblast cell line	the CRISPR/Cas9 system is used to create an ACLY-KO human fibroblast (HF) cell line called C9	746321	
6.2.1.1	foreskin	-	746321	
6.2.1.1	heart	-	563, 567, 570, 572	
6.2.1.1	heart	AceCS2, high activity	652101	
6.2.1.1	HeLa cell	-	744656	
6.2.1.1	hippocampus	-	745887	
6.2.1.1	kidney	-	649297	
6.2.1.1	kidney	AceCS2, high activity	652101	
6.2.1.1	leaf	-	576, 694718	
6.2.1.1	leaf	from plants with altered ACS levels	649463	
6.2.1.1	leaf	highest expression	746504	
6.2.1.1	liver	-	558, 563, 649297, 674377	
6.2.1.1	liver	1.5fold-2fold higher activity of the enzyme in the periportal zone of the male rat liver compared with the perivenous zone in the fed state, but not in the fasted/refed state	575	
6.2.1.1	liver	AceCS1, no AceCS2 activity	652101	
6.2.1.1	LL/2 (LLC1) cell	cells express higher levels of cytosolic acetyl-CoA synthetase ACSS2 under hypoxia than normoxia. Knockdown of ACSS2 by RNA interference in tumor cells enhances tumor cell death under long-term hypoxia in vitro. The ACSS2 suppression slows tumor growth in vivo. Tumor cells excrete acetate and the quantity increases under hypoxia, the pattern of acetate excretion follows the expression pattern of ACSS2. The ACSS2 knockdown leads to a corresponding reduction in the acetate excretion in tumor cells	703038	
6.2.1.1	lung	-	572	
6.2.1.1	lung	AceCS2, high activity	652101	
6.2.1.1	MDA-MB-231 cell	-	744656	
6.2.1.1	MDA-MB-468 cell	-	744656	
6.2.1.1	additional information	no AceCS2 activity is detected in liver. Marked induction of AceCS1 mRNA and protein during differentiation of 3T3-L1 cells, neither AceCS2 mRNA nor protein is detected in undifferentiated or differentiated 3T3-L1 cells	652101	
6.2.1.1	muscle	-	572	
6.2.1.1	mycelium	-	574	
6.2.1.1	myocardium	-	581	
6.2.1.1	neuron	-	745887	
6.2.1.1	phloem	-	746504	
6.2.1.1	prostate cancer cell	-	744620	
6.2.1.1	pupa	newly-pupated pupae of both sexes	580	
6.2.1.1	RCC 786-O cell	-	744665	
6.2.1.1	renal cell carcinoma cell	-	744665	
6.2.1.1	root	-	746504	
6.2.1.1	rumen epithelium	-	557	
6.2.1.1	seed	-	565	
6.2.1.1	shoot	-	649463	
6.2.1.1	skeletal muscle	AceCS2, high activity	652101	
6.2.1.1	spleen	AceCS2, high activity	652101	
6.2.1.1	submaxillary gland	-	649297	
6.2.1.1	testis	-	649297	
6.2.1.1	testis	AceCS2, high activity	652101	
6.2.1.1	xylem	-	746504